Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients
Businesswire
via Businesswire
Updated 1h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
ASM International (OTCMKTS:ASMIY) Upgraded to “Strong-Buy” at Zacks Research
Next
Graham Platner's Tattoo Controversy Isn't Holding Him Back in Senate Race
Related Articles
HealthNewly minted police constable credits visually impaired dad for milestone
Unknown-4h ago-1 sources
HealthSAVAGE HOUSE Trailer Unleashes a Wild 18th Century Comedy with Richard E. Grant and Claire Foy
Geektyrant-13h ago-1 sources
HealthOtsuka Pharmaceutical to Acquire Transcend Therapeutics
Pr Newswire-13h ago-1 sources